Crescent Biopharma (CBIO) Stock Price, News & Analysis

Company Overview

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $13.76 to $14.59
• 50-Day Range: $11.00 to $18.00
• 52-Week Range: $10.83 to $63.00
• Volume: 49,639 shs
• Average Volume: 99,205 shs
• Market Capitalization: $281.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.60
• Consensus Rating: Buy

Crescent Biopharma Stock Analysis - MarketRank™

Crescent Biopharma scored higher than 75% of companies evaluated by MarketBeat, and ranked 261st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.7 / 5
• Analyst Rating: Buy

Consensus Rating

Crescent Biopharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Crescent Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Crescent Biopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Crescent Biopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Crescent Biopharma has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Crescent Biopharma does not currently pay a dividend.

Dividend Growth

Crescent Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -0.84

Short Interest

There is no current short interest data available for CBIO.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.41

News Sentiment

Crescent Biopharma has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Crescent Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Crescent Biopharma is held by insiders.

Percentage Held by Institutions

75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CBIO Stock Analysis - Frequently Asked Questions

How have CBIO shares performed this year?

Crescent Biopharma's stock was trading at $15.7950 at the start of the year. Since then, CBIO shares have decreased by 8.8% and is now trading at $14.40.

How were Crescent Biopharma's earnings last quarter?

Crescent Biopharma, Inc. (NASDAQ:CBIO) announced its quarterly earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($7.00).

When did Crescent Biopharma's stock split?

Shares of Crescent Biopharma reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Crescent Biopharma's major shareholders?

Crescent Biopharma's top institutional shareholders include BVF Inc. IL (7.10%), Commodore Capital LP (2.32%), Perceptive Advisors LLC (2.32%) and Frazier Life Sciences Management L.P. (2.32%).
View institutional ownership trends.

How do I buy shares of Crescent Biopharma?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Crescent Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 8/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• Previous Symbol: NASDAQ:CBIO
• CIK: 1253689
• Web: www.crescentbiopharma.com
• Phone: 617-465-0586
• Fax: 336-480-2107
• Employees: 50
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Crescent Biopharma: $25.60
• High Price Target: $28.00
• Low Price Target: $22.00
• Potential Upside/Downside: +80.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($34.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -106.06%
• Return on Assets: -86.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.21
• Quick Ratio: 9.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.92 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 19,550,000
• Free Float: 18,768,000
• Market Cap: $276.63 million
• Optionable: No Data
• Beta: 1.51